Alkalizing agents for blood purification
Patent Information
- Application Number
- JP2017085741
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-04-18
- Filing Date
- 2017-04-24
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2037-04-24
AI Technical Summary
Existing treatments for chronic kidney disease (CKD) are inadequate in lowering the concentration of uremic substances like indoxyl sulfate, which contribute to renal fibrosis and cardiovascular complications, and there is a lack of evidence that alkalinizing agents effectively suppress the progression of CKD in early stages.
A pharmaceutical composition containing alkalinizing agents such as potassium citrate and sodium citrate is administered to promote the excretion of uremic substances from the body, thereby reducing their concentration in the blood and urine, and potentially delaying the progression of CKD and associated cardiovascular diseases.
The composition effectively lowers blood levels and enhances urinary excretion of uremic substances, improving renal tubular function, reducing the risk of dialysis initiation, and preventing cardiovascular complications in CKD patients.
Abstract
Description
[Technology Field]
[0001] This invention relates to blood purification using an alkalizing agent. [Background technology]
[0002] The number of patients with end-stage kidney disease (ESKD), requiring dialysis or transplantation, is increasing worldwide. This trend is also on the rise in Japan, with 320,000 dialysis patients at the end of 2014. Chronic kidney disease (CKD) is recognized as a precursor to ESKD. CKD is a comprehensive concept encompassing chronic kidney disease, regardless of the underlying disease, and includes all conditions in which there is a decline in renal function, expressed as glomerular filtration rate (GFR), or findings suggestive of kidney damage that persist chronically (for more than 3 months). CKD is not only a risk factor for progression to ESKD, but also a strong risk factor for cardiovascular disease (CVD), etc. Therefore, early detection and appropriate treatment of CKD are extremely important. While many CKD treatments have been established, they are still insufficient, and further development of renal protective agents is needed.
[0003] In chronic kidney disease (CKD), various uremic substances accumulate in the body due to decreased renal clearance. In particular, indoxyl sulfate, a terminal metabolite of tryptophan, increases in blood concentration as CKD progresses, and high concentrations (100 μM to 1 mM) of indoxyl sulfate accumulate in the blood. Indoxyl sulfate is known to be deeply involved in the progression of renal damage due to renal fibrosis and in complications of CKD such as cardiovascular disease (CVD) due to vascular calcification, and there are reports that serum indoxyl sulfate concentration correlates with mortality and cardiovascular event incidence in dialysis patients (Non-Patent Literature 1). It is thought that lowering the blood concentration of indoxyl sulfate in CKD patients can suppress progression to advanced ketoglycemia (ESKD) and reduce the development of CVD associated with renal failure. In fact, a spherical activated carbon preparation (Kremezin®) that adsorbs indole, a precursor of indoxyl sulfate, in the intestinal tract and lowers blood indoxyl sulfate concentration delays the initiation of dialysis in CKD patients and improves arteriosclerosis (Non-Patent Literature 2).
[0004] On the other hand, in patients with advanced CKD, the blood contains bicarbonate ions (HCO3) - As the concentration of acid becomes low, metabolic acidosis develops, so alkalizing agents such as sodium bicarbonate and citrate preparations are administered. It has been reported that the administration of sodium bicarbonate, an alkalizing agent, suppresses the progression of CKD (Non-Patent Literature 3). In addition, in an animal model of nephrotic syndrome, it has been reported that oral administration of sodium bicarbonate suppresses tubular cell damage caused by acidic urine (Non-Patent Literature 4). However, there have been no reports of administering alkalizing agents to early-stage CKD patients suppressing the progression of renal impairment, nor have there been any reports of a decrease in blood concentrations of uremic toxins. [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] Barreto, FC, et al.: Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin. J. Am. Soc. Nephrol., 4: 1551-1558, 2009. [Non-Patent Document 2] Nakamura T., et al.: Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res, 27: 121-6, 2004. [Non-Patent Document 3] Brito-Ashurst, ID, et al.: Bicarbonate supplementation slows progression of CKD and improves nutritional status. J. Am. Soc. Nephrol., 20: 2075-2084, 2009. [Non-Patent Document 4] Souma T., et al.: Luminal alkalinization attenuates proteinuria-induced oxidative damage in proximal tubular cells. J. Am. Soc. Nephrol., 22: 635-648, 2011. [Overview of the Initiative] [Problems that the invention aims to solve]
[0006] One of the objectives of the present invention is to provide a pharmaceutical agent useful for blood purification in patients with kidney disease. Another objective of the present invention is to provide a pharmaceutical agent useful for suppressing the progression of chronic kidney disease (worsening of chronic kidney disease), treating and preventing uremic symptoms, and delaying the initiation of dialysis. Another objective of the present invention is to provide a pharmaceutical agent useful for suppressing the progression from acute kidney disease to chronic kidney disease. Another objective of the present invention is to provide a food product for promoting the excretion of uremic substances from the body. Another objective of the present invention is to provide a method for determining the suppression of the progression of chronic kidney disease, a decrease in the concentration of uremic substances in the blood, and / or promotion of the excretion of uremic substances in the urine. [Means for solving the problem]
[0007] The inventors of this invention conducted diligent research to achieve the above objectives and discovered that an agent that alkalizes body fluids is useful in promoting the excretion of uremic substances from the bodies of patients with kidney disease (for example, promoting the excretion of uremic substances into the urine), thus completing the present invention.
[0008] In one aspect, the present invention provides a pharmaceutical composition for promoting the excretion of uremic substances from the body, comprising an alkalizing agent.
[0009] In one aspect, the present invention provides a pharmaceutical composition for reducing the blood concentration of uremic substances, comprising an alkalizing agent.
[0010] In one aspect, the present invention provides a pharmaceutical composition for promoting the urinary excretion of uremic substances, comprising an alkalizing agent.
[0011] In one aspect, the present invention provides a pharmaceutical composition comprising an alkalizing agent for improving uremic symptoms in chronic kidney disease.
[0012] In one aspect, the present invention provides a pharmaceutical composition comprising an alkalizing agent for delaying the initiation of dialysis in chronic kidney disease.
[0013] In one aspect, the present invention provides a pharmaceutical composition comprising an alkalizing agent for the treatment or prevention of cardiovascular disease associated with chronic kidney disease.
[0014] In one aspect, the present invention provides a pharmaceutical composition containing an alkalizing agent for inhibiting the progression from acute kidney disease to chronic kidney disease.
[0015] In one aspect, the present invention provides a food composition for promoting the excretion of uremic substances from the body, comprising an alkalizing agent.
[0016] In one aspect, the present invention provides a method for determining the suppression of the progression of chronic kidney disease.
[0017] In one aspect, the present invention provides a method for determining a decrease in the concentration of uremic toxins in human blood and / or an increase in the excretion of uremic toxins in urine. [Effects of the Invention]
[0018] The pharmaceutical compositions provided by the present invention allow for the excretion of uremic substances from the body of mammals. The methods provided by the present invention allow for a preliminary determination of whether or not uremic substances are excreted from the body, and / or whether or not the progression of chronic kidney disease is suppressed.
Mode for Carrying Out the Invention
[0019] 1. Pharmaceutical composition In one embodiment, the pharmaceutical composition provided by the present invention contains an alkalizing agent. An alkalizing agent is a drug having the ability to increase the concentration of HCO3 or the pH of body fluids (particularly human) such as blood or urine. Examples of alkalizing agents include pharmaceutically acceptable salts of citric acid, or hydrates thereof or mixtures thereof, and sodium hydrogen carbonate (sodium bicarbonate). Examples of pharmaceutically acceptable salts of citric acid include alkali metal salts of citric acid. Examples of alkali metal salts of citric acid include potassium citrate and sodium citrate, and may be hydrates such as stable potassium citrate monohydrate (C6H5K3O7·H2O) and sodium citrate dihydrate (C6H5Na3O7·2H2O), respectively. Examples of preferred alkalizing agents include sodium citrate, potassium citrate or hydrates thereof or mixtures thereof, for example, a mixture of potassium citrate monohydrate (C6H5K3O7·H2O) and sodium citrate dihydrate (C6H5Na3O7·2H2O) may be used. The mixing ratio of potassium citrate monohydrate (C6H5K3O7·H2O) and sodium citrate dihydrate (C6H5Na3O7·2H2O) can be appropriately set by those skilled in the art. For example, the molar ratio of potassium citrate monohydrate to sodium citrate dihydrate can be 0.01 to 100 with respect to 1 of potassium citrate monohydrate. The mixing ratio may be about 1:1 in terms of molar ratio. Also, other examples of preferred alkalizing agents include sodium citrate or hydrates thereof, for example, sodium citrate dihydrate (C6H5Na3O7·2H2O) may be used. Also, other examples of preferred alkalizing agents include potassium citrate or hydrates thereof, for example, potassium citrate monohydrate (C6H5K3O7·H2O) may be used.
[0020] In this specification, uremic substances refer to substances (such as waste products and toxins) that are excreted by normal kidneys, and when the excretion function decreases due to some cause such as reduced renal function, they increase (accumulate) in the blood and cause uremic symptoms or diseases. Examples of uremic substances include indoxyl sulfate, p-cresyl sulfate, phenylacetyl L-glutamine, hippuric acid, and argininosuccinic acid. Among these, indoxyl sulfate is produced by the oxidation and sulfate conjugation of indole, which is generated by intestinal bacteria from tryptophan derived from dietary protein, in the liver. Most of indoxyl sulfate exists in the blood bound to albumin and does not undergo metabolism. In healthy individuals, it is excreted from the kidneys into the urine, but in patients with kidney disease, due to reduced kidney function, it accumulates in high concentrations in the blood. Indoxyl sulfate, which is a uremic substance, not only causes uremia in patients with kidney disease but also accumulates in tubular cells, causing tubular cell damage and leading to the initiation of dialysis in patients with chronic kidney disease. Therefore, by reducing the concentration of indoxyl sulfate in the blood, the uremic symptoms of patients with kidney disease can be improved, and the treatment and / or prevention of uremia becomes possible. Also, by reducing the concentration of indoxyl sulfate in the blood, tubular cell damage can be suppressed, the function of the tubules (such as the reabsorption of glucose, amino acids, etc.) can be maintained, and the initiation of dialysis in patients with chronic kidney disease can be delayed. In one embodiment, the patient with chronic kidney disease has progressive chronic kidney disease.
[0021] In addition, indoxyl sulfate, which is a uremic substance, causes myocardial fibrosis, arteriosclerosis, proliferation of vascular smooth muscle cells, vascular endothelial cell damage, arterial wall thickening, aortic calcification, etc., and develops cardiovascular diseases (such as heart failure, myocardial infarction, stroke, etc.), which are one of the complications of patients with chronic kidney disease. Therefore, by reducing the concentration of indoxyl sulfate in the blood, myocardial fibrosis, arteriosclerosis, proliferation of vascular smooth muscle cells, vascular endothelial cell damage, arterial wall thickening, aortic calcification, etc. can be suppressed, and the treatment and / or prevention of cardiovascular diseases, which are one of the complications of patients with chronic kidney disease, becomes possible.
[0022] The pharmaceutical compositions provided by the present invention can reduce the concentration of uremic substances in the blood (for example, indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid and / or argininosuccinic acid, preferably indoxyl sulfate and phenylacetyl-L-glutamine, more preferably indoxyl sulfate). Furthermore, the pharmaceutical compositions provided by the present invention can promote the excretion of uremic substances (for example, indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid and / or argininosuccinic acid, preferably indoxyl sulfate, p-cresyl sulfate and / or phenylacetyl-L-glutamine, more preferably indoxyl sulfate and phenylacetyl-L-glutamine, and even more preferably indoxyl sulfate) into the urine. Due to the characteristics of the pharmaceutical composition provided by the present invention, the pharmaceutical composition provided by the present invention can be used not only as a pharmaceutical composition for reducing the blood concentration of uremic substances and / or a pharmaceutical composition for promoting the urinary excretion of uremic substances, but also as any of the following: a pharmaceutical composition for improving uremic symptoms in patients with kidney disease, a pharmaceutical composition for treating and / or preventing uremia in patients with kidney disease, a pharmaceutical composition for suppressing tubular (e.g., proximal tubule) cell damage in patients with kidney disease, a pharmaceutical composition for maintaining tubular function (e.g., proximal tubule) in patients with kidney disease, a pharmaceutical composition for suppressing the progression of chronic kidney disease, and a pharmaceutical composition for delaying the initiation of dialysis in patients with chronic kidney disease. Furthermore, due to the characteristics of the pharmaceutical composition provided by the present invention as described above, the pharmaceutical composition provided by the present invention can also be used as any of the following: a pharmaceutical composition for inhibiting myocardial fibrosis in patients with kidney disease, a pharmaceutical composition for inhibiting arteriosclerosis in patients with kidney disease, a pharmaceutical composition for inhibiting the proliferation of vascular smooth muscle cells in patients with kidney disease, a pharmaceutical composition for inhibiting vascular endothelial cell damage in patients with kidney disease, a pharmaceutical composition for inhibiting arterial wall thickening in patients with kidney disease, a pharmaceutical composition for inhibiting aortic calcification in patients with kidney disease, and a pharmaceutical composition for the treatment and / or prevention of cardiovascular diseases associated with chronic kidney disease.
[0023] Furthermore, it has been reported that when a drug that lowers the blood concentration of indoxyl sulfate was administered to patients with non-diabetic chronic kidney disease, pulse wave velocity and carotid intima-media thickness, which are indicators of arteriosclerosis, significantly improved compared to before administration (Nakamura T., et al.: Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res, 27: 121-6, 2004). Therefore, the pharmaceutical composition provided by the present invention that lowers the blood concentration of indoxyl sulfate can be used as a pharmaceutical composition for improving arteriosclerosis or for improving thickening of arterial (e.g., carotid artery) walls in patients with kidney disease (preferably patients with chronic kidney disease, more preferably patients with non-diabetic chronic kidney disease).
[0024] Furthermore, it has been reported that drugs that lower the blood concentration of indoxyl sulfate suppress cisplatin-induced acute kidney injury (Morisaki T., et. Al.,: Regulation of renal organic ion transporters in cisplatin-induced acute kidney injury and uremia in rats. Pharm. Res., 25(11): 2526-33, 2008). Therefore, the pharmaceutical composition provided by the present invention that lowers the blood concentration of indoxyl sulfate can be used as a pharmaceutical composition for the treatment of acute kidney disease, or as a pharmaceutical composition for suppressing the progression from acute kidney disease to chronic kidney disease.
[0025] Furthermore, p-cresyl sulfate, a uremic substance, has been reported to be a causative agent of vascular endothelial damage (Meijers BK, et. Al.,: The uremic retention solute p-cresyl sulfate and markers of endothelial damage., Am. J. Kidney Dis., 54: 891-901, 2009). Therefore, the pharmaceutical composition provided by the present invention, which promotes the urinary excretion of p-cresyl sulfate, can be used as a pharmaceutical composition for suppressing vascular endothelial damage in patients with kidney disease (preferably patients with chronic kidney disease). Furthermore, phenylacetyl-L-glutamine, a uremic substance, has been reported to increase the risk of developing cardiovascular disease in patients with chronic kidney disease. Therefore, the pharmaceutical composition provided by the present invention, which promotes the urinary excretion of phenylacetyl-L-glutamine, can be used as a pharmaceutical composition for the treatment and / or prevention of cardiovascular disease in patients with chronic kidney disease. The pharmaceutical compositions provided by the present invention promote the urinary excretion of uremic substances such as indoxyl sulfate, p-cresyl sulfate, hippuric acid, argininosuccinic acid, and phenylacetyl-L-glutamine. Therefore, the pharmaceutical compositions provided by the present invention can be used in patients with kidney disease (preferably patients with chronic kidney disease) as pharmaceutical compositions for promoting the urinary excretion of indoxyl sulfate, p-cresyl sulfate, hippuric acid, argininosuccinic acid, and / or phenylacetyl-L-glutamine (for example, a composition for promoting the urinary excretion of indoxyl sulfate and phenylacetyl-L-glutamine, a composition for promoting the urinary excretion of indoxyl sulfate, and a composition for promoting the urinary excretion of phenylacetyl-L-glutamine).
[0026] The pharmaceutical compositions provided by the present invention are administered orally or parenterally to humans or other mammals. Examples of parenteral administration include intravenous, subcutaneous, intramuscular, intra-articular, transmucosal, transdermal, transnasal, rectal, intrathecal, intraperitoneal, and local administration. The pharmaceutical compositions provided by the present invention may be prepared by mixing an alkalizing agent as is, or with pharmaceutically acceptable carriers, such as excipients (e.g., lactose, D-mannitol, crystalline cellulose, glucose), binders (e.g., hydroxypropylcellulose (HPC), gelatin, polyvinylpyrrolidone (PVP)), lubricants (e.g., magnesium stearate, talc), disintegrants (e.g., starch, carboxymethylcellulose calcium (CMC-Ca)), diluents (e.g., water for injection, physiological saline), and, if necessary, other additives (e.g., pH adjusters, surfactants, solubilizers, preservatives, emulsifiers, isotonic agents, stabilizers), and may be in the form of tablets, capsules, suspensions, injections, suppositories, and other formulations. For example, to form tablets, the alkalizing agent may be mixed with excipients (e.g., lactose, D-mannitol, crystalline cellulose, glucose), disintegrants (e.g., starch, carboxymethylcellulose calcium (CMC-Ca)), binders (e.g., hydroxypropylcellulose (HPC), gelatin, polyvinylpyrrolidone (PVP)), lubricants (e.g., magnesium stearate, talc), etc., to form a formulation.
[0027] The amount of alkalizing agent in the pharmaceutical composition provided by the present invention can be set as appropriate. For example, the amount of alkalizing agent administered to a human may be set to an amount that improves acidic urine in gout or hyperuricemia, or to an amount that improves acidosis. The amount of alkalizing agent administered to a human that improves acidic urine in gout or hyperuricemia may be, for example, an amount that, when administered to a human, brings the pH of the human urine (e.g., early morning urine) to pH 6.2 to 6.8 or pH 6.5 to 6.8. In one embodiment, the pharmaceutical composition provided by the present invention is a tablet, and each tablet may contain 10 mg to 1 g, preferably 100 mg to 500 mg, more preferably 400 mg to 500 mg, of potassium citrate monohydrate or sodium citrate dihydrate as an alkalizing agent. Furthermore, in one embodiment, the pharmaceutical composition provided by the present invention is a tablet, and each tablet may contain 10 mg to 300 mg each of potassium citrate monohydrate and sodium citrate dihydrate, for a total of 20 mg to 600 mg, preferably 150 to 250 mg each for a total of 400 to 500 mg, and more preferably 190 to 240 mg each for a total of 400 to 450 mg. In another embodiment, the pharmaceutical composition provided by the present invention is a tablet, and each tablet may contain 10 mg to 1 g, preferably 100 mg to 500 mg, of sodium bicarbonate as an alkalizing agent. Furthermore, in one embodiment, the pharmaceutical composition provided by the present invention is a tablet containing 231.5 mg of potassium citrate monohydrate and 195.0 mg of sodium citrate dihydrate as alkalizing agents, and may also contain anhydrous citric acid, crystalline cellulose, partially pregelatinized starch, hydroxypropyl cellulose, magnesium stearate, hypromellose, macrogol 6000, titanium dioxide, and carnauba wax as additives.
[0028] The dosage of the alkalizing agent should be determined appropriately according to the type of alkalizing agent, the method of administration, the age, weight, sex, symptoms, and sensitivity to the drug of the recipient, but the dosage may be adjusted according to the improvement of symptoms. In one embodiment, when a mixture of potassium citrate monohydrate and sodium citrate dihydrate is orally administered to a human as an alkalizing agent, potassium citrate monohydrate and sodium citrate dihydrate may be administered in doses of 0.1 to 5 g / day each, totaling 0.2 to 10 g / day; 0.1 to 3 g / day each, totaling 0.2 to 6 g / day; 0.5 to 3 g / day each, totaling 1 to 6 g / day; preferably, 0.5 to 1.5 g / day each, totaling 1 to 3 g / day; 1 to 1.5 g / day each, totaling 2 to 3 g / day; or 0.5 to 1 g / day each, totaling 1 to 2 g / day, administered 1 to 5 times a day, preferably divided into 3 doses per day. In one embodiment, when potassium citrate monohydrate or sodium citrate dihydrate is administered orally to humans as an alkalizing agent, the dosage may be 1 to 10 g / day, 1 to 6 g / day, 2 to 5.5 g / day, 1 to 3 g / day, 2 to 3 g / day, or 1 to 1.5 g / day, and may be administered 1 to 5 times a day, preferably divided into 3 doses per day. In one embodiment, when sodium bicarbonate is administered orally to humans as an alkalizing agent, 1 to 6 g / day, preferably 3 to 5 g / day may be administered, and it may be administered 1 to 5 times a day, preferably in 3 divided doses a day.
[0029] In one embodiment, the alkalizing agent may be administered for a long period of time, for example, for 1 week or more, 2 weeks or more, 3 weeks or more, 6 weeks or more, 8 weeks or more, 10 weeks or more, 12 weeks or more, 24 weeks or more, 6 weeks or more and 24 weeks or less, 12 weeks or more and 24 weeks or less, or 12 weeks or more and 30 weeks or less. In one embodiment, when a mixture of potassium citrate monohydrate and sodium citrate dihydrate is orally administered to humans as an alkalizing agent, the blood concentration of indoxyl sulfate begins to decrease compared to before administration between 6 and 12 weeks from the start of administration, and its urinary excretion begins to increase compared to before administration. Also in this embodiment, the urinary excretion of p-cresyl sulfate begins to increase compared to before administration between 6 and 12 weeks from the start of administration, the blood concentration of hippuric acid begins to decrease compared to before administration between 12 and 24 weeks from the start of administration, and the urinary excretion of hippuric acid begins to increase compared to before administration between 0 and 6 weeks from the start of administration. Furthermore, in this embodiment, the urinary excretion of argininosuccinate begins to increase compared to before administration between 6 and 12 weeks from the start of administration, and the urinary excretion of phenylacetyl-L-glutamine begins to increase compared to before administration between 6 and 12 weeks from the start of administration. Considering the embodiments described above, when a mixture of potassium citrate monohydrate and sodium citrate dihydrate is orally administered to humans, it may be administered for, for example, 6 weeks or more, preferably 12 weeks or more, and more preferably 24 weeks or more.
[0030] In one embodiment, the pharmaceutical composition provided by the present invention is administered to a person suffering from kidney disease. Unless otherwise specified, kidney disease includes acute kidney disease and chronic kidney disease. Examples of acute kidney disease include acute kidney disease caused by medications (e.g., nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, aminoglycoside antibiotics, fluoroquinolone antibacterial agents, iodine contrast agents, platinum-based drugs such as cisplatin), and acute kidney disease caused by renal ischemia. Chronic kidney disease (CKD) is a comprehensive concept encompassing all kidney diseases that progress chronically, regardless of the underlying disease. It includes all conditions in which there is a decline in renal function, expressed as glomerular filtration rate (GFR), or where findings suggestive of kidney damage persist chronically (for three months or more).
[0031] According to the CKD Treatment Guidelines 2012 (Japanese Journal of Nephrology 2012), the severity of chronic kidney disease is evaluated by classification based on the cause (C), renal function (GFR: G), and proteinuria (albuminuria: A). The GFR classifications are as follows: G1: GFR is normal or elevated (≧90 mL / min / 1.73 m) 2 ) G2: GFR is normal or slightly decreased (60-89 mL / min / 1.73 m²) 2 ) G3a: Mild to moderate decrease in GFR (45-59 mL / min / 1.73 m²) 2 ) G3b: Moderate to severe decrease in GFR (30-44 mL / min / 1.73 m²) 2 ) G4: Severely decreased GFR (15-29 mL / min / 1.73 m²) 2 ) G5: End-stage renal disease (ESKD) (<15 mL / min / 1.73 m 2 ) When the underlying disease is diabetes, the classification of proteinuria (albuminuria: A) is determined using the urinary albumin / creatinine (Cr) ratio as follows: A1: Normal (less than 30 mg / gCr) A2: Microalbuminuria (30-299 mg / gCr) A3: Overt albuminuria (≥300 mg / gCr) Furthermore, when the underlying disease is hypertension other than diabetes, nephritis, polycystic kidney disease, transplanted kidney, or other conditions, the classification based on proteinuria (albuminuria: A) is made using the urinary protein / creatinine (Cr) ratio as follows. A1: Normal (less than 0.15 g / gCr) A2: Mild proteinuria (0.15-0.49 g / gCr) A3: Severe proteinuria (0.50 g / gCr or more) According to the 2012 CKD Treatment Guidelines (2012 Journal of the Japanese Society of Nephrology), the severity classification of chronic kidney disease (CKD) is expressed using the above C, G, and A, for example, diabetes G2A3, chronic nephritis G3bA1, etc. However, considering that the severity of chronic kidney disease has traditionally been expressed only in terms of stages classified by GFR, it is also possible to express the severity of chronic kidney disease in the traditional way, using stages G1, G2, G3a, G3b, G4, and G5.
[0032] In one embodiment, the pharmaceutical composition provided by the present invention is administered to patients with early-stage chronic kidney disease with low severity. In one embodiment, the pharmaceutical composition provided by the present invention is administered to patients with chronic kidney disease of stage G3b or lower, preferably stage G2 or lower. In one embodiment, the pharmaceutical composition provided by the present invention is administered to patients with chronic kidney disease in stage G3b or lower, with a urinary protein excretion of less than 3.5 g / gCr, preferably in stage G2, with a urinary protein excretion of less than 3.5 g / gCr. In one embodiment, the pharmaceutical composition provided by the present invention is administered to a patient with progressive chronic kidney disease.
[0033] In one embodiment, the pharmaceutical composition provided by the present invention is administered to patients receiving treatment in accordance with the CKD treatment guidelines. For example, it is administered to patients receiving blood pressure management (administration of RA system inhibitors such as ARBs and ACE inhibitors, diuretics, calcium channel blockers, etc.), proteinuria management (administration of RA system inhibitors, etc.), blood glucose management (administration of α-glucosidase inhibitors, etc.), lipid management (administration of statins, fibrates, etc.), anemia management (administration of erythropoietin, etc.), and / or bone and mineral management (administration of bisphosphonates, etc.) in accordance with the CKD treatment guidelines.
[0034] In one embodiment, the pharmaceutical composition provided by the present invention is administered to patients with mild, early-stage chronic kidney disease (e.g., patients with stage G3b or lower, preferably stage G2 chronic kidney disease) to reduce the concentration of uremic substances (e.g., indoxyl sulfate and / or phenylacetyl-L-glutamine) in the patient's blood and to promote the excretion of uremic substances (e.g., indoxyl sulfate, p-cresyl sulfate, hippuric acid, argininosuccinate and / or phenylacetyl-L-glutamine) from the body (e.g., into the urine). In this embodiment, the pharmaceutical composition provided by the present invention may be a pharmaceutical composition for improving uremic symptoms, a pharmaceutical composition for treating or preventing uremia, a pharmaceutical composition for inhibiting tubular (e.g., proximal tubular) cell damage, a pharmaceutical composition for maintaining the function of tubular (e.g., proximal tubular) cells, a pharmaceutical composition for inhibiting the progression of chronic kidney disease, a pharmaceutical composition for delaying the initiation of dialysis, a pharmaceutical composition for inhibiting myocardial fibrosis, a pharmaceutical composition for inhibiting arteriosclerosis, a pharmaceutical composition for improving arteriosclerosis, a pharmaceutical composition for inhibiting the proliferation of vascular smooth muscle cells, a pharmaceutical composition for inhibiting vascular endothelial cell damage, a pharmaceutical composition for inhibiting arterial wall thickening, a pharmaceutical composition for improving arterial wall thickening, a pharmaceutical composition for inhibiting aortic calcification, or a pharmaceutical composition for treating or preventing cardiovascular diseases (e.g., heart failure, myocardial infarction, stroke, etc.) that are complications. In one embodiment, the pharmaceutical composition provided by the present invention is administered to patients with moderate to severe chronic kidney disease (e.g., patients with stage G3b or higher, preferably stage G4 or higher) to reduce the concentration of uremic substances (e.g., indoxyl sulfate and / or phenylacetyl-L-glutamine) in the patient's blood and to promote the excretion of uremic substances (e.g., indoxyl sulfate, p-cresyl sulfate, hippuric acid, argininosuccinate and / or phenylacetyl-L-glutamine) from the body (e.g., into the urine). In this embodiment, the pharmaceutical composition provided by the present invention may be a pharmaceutical composition for improving uremic symptoms, a pharmaceutical composition for treating or preventing uremia, a pharmaceutical composition for inhibiting tubular (e.g., proximal tubular) cell damage, a pharmaceutical composition for maintaining tubular (e.g., proximal tubular) cell function, a pharmaceutical composition for inhibiting the progression of chronic kidney disease, a pharmaceutical composition for delaying the initiation of dialysis, a pharmaceutical composition for inhibiting myocardial fibrosis, a pharmaceutical composition for inhibiting arteriosclerosis, a pharmaceutical composition for improving arteriosclerosis, a pharmaceutical composition for inhibiting the proliferation of vascular smooth muscle cells, a pharmaceutical composition for inhibiting vascular endothelial cell damage, a pharmaceutical composition for inhibiting arterial wall thickening, a pharmaceutical composition for improving arterial wall thickening, a pharmaceutical composition for inhibiting aortic calcification, or a pharmaceutical composition for treating or preventing cardiovascular diseases (e.g., heart failure, myocardial infarction, stroke, etc.) that are complications.
[0035] Other examples of embodiments of the present invention include the following. a) A method for reducing the blood concentration of uremic substances in a mammalian subject (e.g., a human), comprising administering an effective amount of an alkalizing agent to a subject in which it is necessary to reduce the blood concentration of uremic substances; b) A method for promoting the excretion of uremic substances from the body (e.g., into urine) in a mammalian subject (e.g., human), comprising administering an effective amount of an alkalizing agent to a subject for which it is necessary to promote the excretion of uremic substances from the body (e.g., into urine); c) A method for improving uremic symptoms in a mammal (e.g., a human), comprising administering an effective amount of an alkalizing agent to a subject in need of improvement of uremic symptoms, wherein the subject is suffering from kidney disease; d) A method for treating or preventing uremia in a mammal (e.g., a human), comprising administering an effective amount of an alkalizing agent to a subject in need of treatment or prevention of uremia, wherein the subject is suffering from kidney disease; e) A method for suppressing tubular (e.g., proximal tubular) cell damage in a mammalian subject (e.g., human), comprising administering an effective amount of an alkalizing agent to a subject in which suppression of tubular (e.g., proximal tubular) cell damage is necessary, wherein the subject is suffering from kidney disease; f) A method for maintaining tubular (e.g., proximal tubular) cell function in a mammalian subject (e.g., human), comprising administering an effective amount of an alkalizing agent to a subject in which it is necessary to maintain the function of tubular (e.g., proximal tubular) cells, wherein the subject is suffering from kidney disease; g) A method for inhibiting the progression of chronic kidney disease in a mammal (e.g., human), comprising administering an effective amount of an alkalizing agent to a subject in which the progression of chronic kidney disease needs to be inhibited; h) A method for delaying the initiation of dialysis in a mammalian subject (e.g., human), comprising administering an effective amount of an alkalizing agent to a subject in need of delaying the initiation of dialysis, wherein the subject is suffering from chronic kidney disease; i) A method for inhibiting myocardial fibrosis in a mammalian subject (e.g., human), comprising administering an effective amount of an alkalizing agent to a subject in which inhibition of myocardial fibrosis is necessary, wherein the subject is suffering from kidney disease; j) A method for inhibiting arteriosclerosis in a mammal (e.g., a human), comprising administering an effective amount of an alkalizing agent to a subject in which inhibiting arteriosclerosis is necessary, wherein the subject is suffering from kidney disease; k) A method for inhibiting the proliferation of vascular smooth muscle cells in a mammalian subject (e.g., human), comprising administering an effective amount of an alkalizing agent to a subject in which the proliferation of vascular smooth muscle cells needs to be inhibited, wherein the subject is suffering from kidney disease; l) A method for suppressing vascular endothelial cell damage in a mammalian subject (e.g., human), comprising administering an effective amount of an alkalizing agent to a subject in which suppression of vascular endothelial cell damage is necessary, wherein the subject is suffering from kidney disease; m) A method for suppressing arterial wall thickening in a mammalian subject (e.g., human), comprising administering an effective amount of an alkalizing agent to a subject in which suppression of arterial wall thickening is necessary, wherein the subject is suffering from kidney disease; n) A method for inhibiting aortic calcification in a mammalian subject (e.g., human), comprising administering an effective amount of an alkalizing agent to a subject in which inhibiting aortic calcification is necessary, wherein the subject is suffering from kidney disease; o) A method for treating or preventing cardiovascular disease in a mammalian subject (e.g., human), comprising administering an effective amount of an alkalizing agent to a subject in need of treatment or prevention of cardiovascular disease, wherein the subject is suffering from kidney disease; p) A method for improving arteriosclerosis in a mammal (e.g., a human), comprising administering an effective amount of an alkalizing agent to a subject in need of improvement of arteriosclerosis, wherein the subject is suffering from kidney disease; q) A method for improving arterial wall thickening in a mammalian subject (e.g., human), comprising administering an effective amount of an alkalizing agent to a subject that needs improvement in arterial wall thickening, wherein the subject is suffering from kidney disease; r) A method for treating acute kidney disease in a mammal (e.g., human), comprising administering an effective amount of an alkalizing agent to a subject in need of treatment for acute kidney disease; s) A method for inhibiting the progression from acute kidney disease to chronic kidney disease in a mammal (e.g., human), comprising administering an effective amount of an alkalizing agent to a subject in need of inhibiting the progression from acute kidney disease to chronic kidney disease; aa) Alkalinizing agents for use as agents to lower the blood concentration of uremic substances; bb) Alkalinizing agents for use as excretion promoters of uremic toxins from the body (e.g., into urine); cc) An alkalizing agent for use as an agent to improve uremic symptoms in patients with kidney disease; dd) An alkalizing agent for use as a treatment or prophylactic agent for uremia in patients with kidney disease; ee) An alkalizing agent for use as an inhibitor of tubular (e.g., proximal tubular) cytotoxicity in patients with kidney disease; ff) An alkalizing agent for use as a tubular (e.g., proximal tubule) cell function maintenance agent in patients with kidney disease; gg) An alkalizing agent used as a treatment to slow the progression of chronic kidney disease; hh) An alkalizing agent for use as a delaying agent for the initiation of dialysis in patients with chronic kidney disease; ii) An alkalizing agent for use as an inhibitor of myocardial fibrosis in patients with kidney disease; jj) An alkalizing agent for use as an anti-atherosclerosis agent in patients with kidney disease; kk) An alkalizing agent for use as an inhibitor of vascular smooth muscle cell proliferation in patients with kidney disease; ll) An alkalizing agent for use as an inhibitor of vascular endothelial cell damage in patients with kidney disease; (mm) An alkalizing agent for use as an inhibitor of arterial wall thickening in patients with kidney disease; nn) An alkalizing agent for use as an inhibitor of aortic calcification in patients with kidney disease; oo) An alkalizing agent for use as a treatment or prophylactic agent for cardiovascular disease in patients with kidney disease; pp) An alkalizing agent for use as an agent to improve arteriosclerosis in patients with kidney disease; qq) An alkalizing agent for use as an agent to improve arterial wall thickening in patients with kidney disease; rr) An alkalizing agent for use as a treatment for acute kidney disease; ss) An alkalizing agent used to inhibit the progression from acute kidney disease to chronic kidney disease; aaa) Alkalinizing agents for use in reducing blood concentrations of uremic substances; bbb) Alkalinizing agent for use in promoting the excretion of uremic substances into the urine; ccc) An alkalizing agent for use in improving uremic symptoms in patients with kidney disease; ddd) An alkalizing agent for use in the treatment or prevention of uremia in patients with kidney disease; eee) An alkalizing agent for use in suppressing tubular (e.g., proximal tubular) cell damage in patients with kidney disease; fff) An alkalizing agent for use in maintaining tubular (e.g., proximal tubular) cell function in patients with kidney disease; ggg) Alkalizing agent for use in inhibiting the progression of chronic kidney disease; hhh) Alkalinizing agent for use in delaying the initiation of dialysis in patients with chronic kidney disease; iii) Alkalinizing agents for use in inhibiting myocardial fibrosis in patients with kidney disease; jjj) Alkalinizing agent for use in suppressing arteriosclerosis in patients with kidney disease; kkk) Alkalizing agent for use in inhibiting the proliferation of vascular smooth muscle cells in patients with kidney disease; 3) An alkalizing agent for use in suppressing vascular endothelial cell damage in patients with kidney disease; An alkalizing agent for use in inhibiting arterial wall thickening in patients with kidney disease; nnn) An alkalizing agent for use in inhibiting aortic calcification in patients with kidney disease; ooo) An alkalizing agent for use in the treatment or prevention of cardiovascular disease in patients with kidney disease; (ppp) An alkalizing agent for use in improving arteriosclerosis in patients with kidney disease; qqq) An alkalizing agent for use in improving arterial wall thickening in patients with kidney disease; rrr) Alkalinizing agent for use in the treatment of acute kidney disease; sss) Alkalinizing agent for use in inhibiting the progression from acute kidney disease to chronic kidney disease; aaaa) Use of alkalizing agents for manufacturing pharmaceutical compositions for reducing blood concentrations of uremic substances; bbbb) Use of alkalizing agents for manufacturing pharmaceutical compositions for promoting the excretion of uremic substances from the body (e.g., into urine); cccc) Use of alkalizing agents for manufacturing pharmaceutical compositions for improving uremic symptoms in patients with kidney disease; dddd) Use of alkalizing agents for the manufacture of pharmaceutical compositions for the treatment or prevention of uremia in patients with kidney disease; eeee) Use of an alkalizing agent for manufacturing a pharmaceutical composition for inhibiting tubular (e.g., proximal tubular) cell damage in patients with kidney disease; ffff) Use of an alkalizing agent for manufacturing a pharmaceutical composition for maintaining tubular (e.g., proximal tubular) cell function in patients with kidney disease; gggg) Use of alkalizing agents for manufacturing pharmaceutical compositions for inhibiting the progression of chronic kidney disease; hhhh) Use of alkalizing agents for manufacturing pharmaceutical compositions for delaying the initiation of dialysis in patients with chronic kidney disease; iiii) Use of alkalizing agents for manufacturing pharmaceutical compositions for inhibiting myocardial fibrosis in patients with kidney disease; jjjj) Use of alkalizing agents for manufacturing pharmaceutical compositions for inhibiting arteriosclerosis in patients with kidney disease; kkkk) Use of an alkalizing agent for manufacturing a pharmaceutical composition for inhibiting the proliferation of vascular smooth muscle cells in patients with kidney disease; ll) Use of an alkalizing agent for manufacturing a pharmaceutical composition for inhibiting vascular endothelial cell damage in patients with kidney disease; Use of an alkalizing agent for manufacturing a pharmaceutical composition for inhibiting arterial wall thickening in patients with kidney disease; nnnn) Use of an alkalizing agent for manufacturing a pharmaceutical composition for inhibiting aortic calcification in patients with kidney disease; oooo) Use of alkalizing agents for manufacturing pharmaceutical compositions for the treatment or prevention of cardiovascular disease in patients with kidney disease; pppp) Use of alkalizing agents for manufacturing pharmaceutical compositions for improving arteriosclerosis in patients with kidney disease; qqqq) Use of an alkalizing agent for manufacturing a pharmaceutical composition for improving arterial wall thickening in patients with kidney disease; rrrr) Use of alkalizing agents for manufacturing pharmaceutical compositions for the treatment of acute kidney disease; and ssss) Use of an alkalizing agent for manufacturing a pharmaceutical composition for inhibiting the progression from acute kidney disease to chronic kidney disease. In the embodiments a) to sss) described above, the alkalizing agent may be a pharmaceutically acceptable salt of citric acid, its hydrate, or a mixture thereof, or sodium bicarbonate. Examples of pharmaceutically acceptable salts of citric acid include alkali metal citrate salts, and examples of alkali metal citrate salts include potassium citrate and sodium citrate, which may be stable monohydrates of potassium citrate (C6H5K3O7·H2O) and dihydrates of sodium citrate (C6H5Na3O7·2H2O), respectively. Examples of preferred alkalizing agents include sodium citrate, potassium citrate, their hydrates, or mixtures thereof. For example, a mixture of potassium citrate monohydrate (C6H5K3O7·H2O) and sodium citrate dihydrate (C6H5Na3O7·2H2O) may be used. The mixing ratio of potassium citrate monohydrate (C6H5K3O7·H2O) and sodium citrate dihydrate (C6H5Na3O7·2H2O) can be appropriately set by those skilled in the art. For example, the molar ratio of potassium citrate monohydrate to sodium citrate dihydrate can be 1 part potassium citrate monohydrate to 0.01 to 100 parts sodium citrate dihydrate. The mixing ratio may also be approximately 1:1 in molar ratio. Other examples of preferred alkalizing agents include sodium citrate or its hydrate, which may be sodium citrate dihydrate (C6H5Na3O7·2H2O). Other examples of preferred alkalizing agents include potassium citrate or its hydrate, which may be, for example, potassium citrate monohydrate (C6H5K3O7·H2O). The amount of alkalizing agent can be set as appropriate. For example, if the alkalizing agent is selected from the group consisting of potassium citrate monohydrate, sodium citrate dihydrate, a mixture of potassium citrate monohydrate and sodium citrate dihydrate, and sodium bicarbonate, the amount may be 10 mg to 1 g, preferably 100 mg to 500 mg, and more preferably 400 mg to 500 mg. The amount of alkalizing agent administered may be such that, upon administration to a human, it improves acidic urine in gout or hyperuricemia, or it may be such that it improves acidosis. For example, the amount of alkalizing agent in the pharmaceutical composition provided by the present invention may be set so that, upon administration of the alkalizing agent, the pH of human urine (e.g., early morning urine) becomes pH 6.2 to 6.8 or pH 6.5 to 6.8. In one embodiment, when a mixture of potassium citrate monohydrate and sodium citrate dihydrate is orally administered to a human as an alkalizing agent, potassium citrate monohydrate and sodium citrate dihydrate may be administered in doses of 0.1 to 5 g / day each, totaling 0.2 to 10 g / day; 0.1 to 3 g / day each, totaling 0.2 to 6 g / day; 0.5 to 3 g / day each, totaling 1 to 6 g / day; preferably, 0.5 to 1.5 g / day each, totaling 1 to 3 g / day; 1 to 1.5 g / day each, totaling 2 to 3 g / day; or 0.5 to 1 g / day each, totaling 1 to 2 g / day, administered 1 to 5 times a day, preferably divided into 3 doses per day. In one embodiment, when potassium citrate monohydrate or sodium citrate dihydrate is administered orally to humans as an alkalizing agent, the dosage may be 1 to 10 g / day, 1 to 6 g / day, 2 to 5.5 g / day, 1 to 3 g / day, 2 to 3 g / day, or 1 to 1.5 g / day, and may be administered 1 to 5 times a day, preferably divided into 3 doses per day. In one embodiment, when sodium bicarbonate is administered orally to humans as an alkalizing agent, 1 to 6 g / day, preferably 3 to 5 g / day may be administered, and it may be administered 1 to 5 times a day, preferably in 3 divided doses a day. In one embodiment, the alkalizing agent may be administered for a long period of time, for example, for 1 week or more, 2 weeks or more, 3 weeks or more, 6 weeks or more, 8 weeks or more, 10 weeks or more, 12 weeks or more, 24 weeks or more, 6 weeks or more and 24 weeks or less, 12 weeks or more and 24 weeks or less, or 12 weeks or more and 30 weeks or less. In the embodiments a) to sss) above, examples of kidney disease include acute kidney disease and chronic kidney disease. Examples of chronic kidney disease include chronic kidney disease of stage 3b or lower (e.g., stage 2), chronic kidney disease of stage 3b or lower (e.g., stage 2) in which the patient's urinary protein excretion is less than 3.5 g / gCr, and chronic kidney disease of stage 3b or higher (e.g., stage 4 or higher). In one embodiment, a kidney disease patient may be a patient receiving treatment in accordance with the CKD treatment guidelines. For example, the patient may be a patient receiving blood pressure management (administration of RA system inhibitors such as ARBs and ACE inhibitors, diuretics, calcium channel blockers, etc.), proteinuria management (administration of RA system inhibitors, etc.), blood glucose management (administration of α-glucosidase inhibitors, etc.), lipid management (administration of statins, fibrates, etc.), anemia management (administration of erythropoietin, etc.), and / or bone and mineral management (administration of bisphosphonates, etc.) in accordance with the CKD treatment guidelines.
[0036] 2. Food composition In one embodiment, the food composition provided by the present invention contains an alkalizing agent and exhibits an effect of promoting the excretion of uremic substances (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid and / or argininosuccinic acid) from the body. The alkalizing agent is as described in "1. Pharmaceutical Composition" above. Examples of alkalizing agents include pharmaceutically acceptable salts of citric acid (e.g., alkali metal salts of citrate or their hydrates or mixtures thereof), sodium bicarbonate, and preferably a mixture of potassium citrate monohydrate (C6H5K3O7·H2O) and sodium citrate dihydrate (C6H5Na3O7·2H2O), or sodium citrate dihydrate. The uremic substances are as described in "1. Pharmaceutical Compositions" above. Examples of uremic substances include indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid, and argininosuccinic acid. The content of the alkalizing agent in the food composition provided by the present invention can be appropriately determined depending on the type of food. Examples of food compositions include foods for specified health uses, nutritional supplements, functional foods, foods for hospital patients, and supplements. The food compositions provided by the present invention can be manufactured by those skilled in the art depending on the type of food, and can be manufactured, for example, by blending an alkalizing agent (e.g., potassium citrate and / or sodium citrate) with food ingredients.
[0037] 3. Methods for determining a decrease in the concentration of uremic substances in the blood, etc. In one embodiment, the present invention provides a method for determining a decrease in the concentration of uremic substances (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid and / or argininosuccinate) in the blood of a patient with chronic kidney disease, the method comprising measuring the pH of the urine. Furthermore, in one embodiment, the present invention provides a method for determining the promotion of excretion of uremic substances (indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid and / or argininosuccinate) in the urine of patients with chronic kidney disease, the method comprising measuring the pH of the urine. The content of uremic substances (e.g., indoxyl sulfate) in body fluids can be measured by HPLC or enzymatic methods. However, these methods require specialized and expensive reagents. As described herein, administering an alkalizing agent lowers uremic substances in the blood (e.g., indoxyl sulfate concentration, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid, and / or argininosuccinate) and promotes their excretion in the urine. Therefore, patients with chronic kidney disease can easily and inexpensively determine the decrease in uremic substances in the blood (e.g., indoxyl sulfate concentration, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid, and / or argininosuccinate) and / or the promotion of their excretion in the urine (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid, and / or argininosuccinate) by measuring the pH of their urine. pH can be measured using well-known techniques, such as pH test strips, pH test solutions, or simple pH meters. In one embodiment, a patient with chronic kidney disease can measure the pH of their early morning urine (the first urine produced after waking up) over time from the start of taking an alkalizing agent (e.g., a mixture of potassium citrate monohydrate and sodium citrate dihydrate, or sodium citrate dihydrate). If the pH of the urine increases, it can be easily determined that a decrease in the concentration of uremic substances in the blood (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid, and / or argininosuccinate) and / or promotion of the excretion of uremic substances in the urine (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid, and / or argininosuccinate) has been achieved. Furthermore, in one embodiment, a patient with chronic kidney disease can measure the pH of their early morning urine (the first urine produced after waking up) after taking an alkalizing agent (for example, a mixture of potassium citrate monohydrate and sodium citrate dihydrate, or sodium citrate dihydrate). If the pH of the urine is in the range of 6.2 to 6.8 (for example, 6.5 to 6.8), it can be easily determined that a decrease in the concentration of uremic substances in the blood (for example, indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid, and / or argininosuccinate) and / or promotion of the excretion of uremic substances in the urine (for example, indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid, and / or argininosuccinate) has been achieved. Determining whether a reduction in the concentration of uremic substances in the blood (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid, and / or argininosuccinate) and / or promotion of the excretion of uremic substances in the urine (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid, and / or argininosuccinate) has been achieved in this manner can be helpful in diagnosing whether the progression of chronic kidney disease has been suppressed. Therefore, in one embodiment, the present invention provides a method for determining the suppression of the progression of chronic kidney disease, comprising measuring the pH of the urine (e.g., early morning urine) of a patient who has been administered an alkalizing agent (e.g., a mixture of potassium citrate monohydrate and sodium citrate dihydrate, or sodium citrate dihydrate). If an increase in urine pH over time, or if the urine pH is in the range of 6.2 to 6.8 (e.g., the urine pH is in the range of 6.5 to 6.8), is observed, it may be helpful in diagnosing that the progression of chronic kidney disease is being suppressed.
[0038] The present invention will be further described below with reference to examples, but the present invention is not limited thereto. [Examples]
[0039] To examine whether oral administration of a formulation containing potassium citrate-sodium citrate hydrate, an oral alkalizing agent, and a sodium bicarbonate formulation promotes the urinary excretion of uremic substances, a human clinical trial was conducted.
[0040] 1. Method Forty-seven patients with chronic kidney disease at stages G2 to G3b (eGFR: 30 to 89 ml / min / 1.73m 2 , urinary protein excretion less than 3.5 g / gCr) were randomly divided into a group administered a formulation containing potassium citrate-sodium citrate hydrate (Group A: 16 patients), a group administered a sodium bicarbonate formulation (Group B: 16 patients), and a control group (Group C: 15 patients). Each group received treatment based on the "CKD Treatment Guidelines - Summary of Treatment" (hereinafter referred to as standard treatment). The control group was not administered an alkalizing agent. Group A was orally administered 3 tablets per day, 3 times a day (morning, noon, evening) for 24 weeks with tablets containing 231.5 mg of potassium citrate (C6H5K3O7·H2O) and 195.0 mg of sodium citrate hydrate (C6H5Na3O7·2H2O). For cases where the early morning urine pH was less than 6.5, the dose was increased to 6 tablets per day, 3 times a day (morning, noon, evening) at the discretion of the physician. Group B was orally administered 3 tablets per day, 3 times a day (morning, noon, evening) for 24 weeks with tablets containing 500 mg of sodium bicarbonate. For cases where the early morning urine pH was less than 6.5, the dose was increased to 6 tablets per day, 3 times a day (morning, noon, evening) at the discretion of the physician. Early morning urine and blood samples were collected at the start of administration, and at 6, 12, and 24 weeks after the start of administration. Each sample was stored at -80°C. Indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid, and argininosuccinate in urine and plasma were quantitatively analyzed using the following liquid chromatography-quadrupole mass spectrometer (LC-MS / MS), referring to methods used in this field (e.g., Sato, E., et. al., Metabolic alteration by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease., Sci Rep. 2016 Nov 10;6:36618. doi: 10.1038 / srep36618.). For LC, a NANOSPACE SI-2 (manufactured by Shiseido) was used, and a CAPCELLPAK MGIII was selected as the analytical column. MS was performed using a TSQ Quantiva (Thermo Fisher Scientific) to ionize five compounds in negative in-mode and detect them using the Selected Reaction Monitoring method. Quantitative values were calculated using calibration curves created with standard solutions of each compound. Statistical analysis was performed using the Mann-Whitney test.
[0041] 2.Results Based on the measurement results using LC-MS / MS, the following was calculated for each patient in Group A (potassium citrate / sodium citrate hydrate preparation), Group B (sodium bicarbonate preparation preparation), and Group C (control group): (i) Concentrations of each uremic substance in plasma at the start of administration (ii) Concentrations of each uremic substance in the early morning urine at the start of administration (iii) The ratio of the concentration of uremic substances in the early morning urine to the concentration of uremic substances in the plasma at the start of administration (amount of uremic substances in urine / amount of uremic substances in plasma) (iv) Concentrations of each uremic substance in plasma at 6, 12, and 24 weeks after the start of administration. (v) Concentrations of each uremic substance in early morning urine at 6, 12, and 24 weeks after the start of administration. (vi) The ratio of the concentration of uremic substances in the first morning urine to the concentration of uremic substances in the plasma at 6, 12, and 24 weeks after the start of administration (amount of uremic substances in urine / amount of uremic substances in plasma) (vii) Changes in the concentration of each uremic toxin in plasma from the start of administration at 6, 12, and 24 weeks after the start of administration. (viii) Changes from the start of administration in the concentration of each uremic substance in the early morning urine at 6, 12, and 24 weeks after the start of administration. (ix) Change from the start of administration in the ratio of uremic substance concentration in early morning urine to uremic substance concentration in plasma (amount of uremic substance in urine / amount of uremic substance in plasma) at 6, 12, and 24 weeks after the start of administration. Then, for each of the above (i) to (ix), the mean and standard deviation (SD) were calculated for each group. For each of the above (iv) to (ix), the mean and SD were calculated for each group using all data from 6 weeks, 12 weeks, and 24 weeks after the start of administration. The results are shown in the table below. In the table, Group A, the group administered a potassium citrate / sodium citrate hydrate preparation, is labeled "Citrate," and Group B, the group administered a sodium bicarbonate preparation, is labeled "Bicarbonate." The numbers in parentheses in the table indicate the number of cases. Table 1-1-1: Plasma levels of indoxyl sulfate (μg / mL), Table 1-1-2: Change in indoxyl sulfate in plasma from the start of administration (μg / mL), Table 1-2-1: Amount of indoxyl sulfate in early morning urine (μg / mL), Table 1-2-2: Change in indoxyl sulfate in early morning urine since the start of administration (μg / mL), Table 1-3-1: Ratio of indoxyl sulfate amount in urine to indoxyl sulfate amount in plasma. Table 1-3-2: Change from the start of administration in the ratio of indoxyl sulfate in urine to indoxyl sulfate in plasma. Table 2-1-1: Amount of p-cresil sulfate in plasma (μg / mL), Table 2-1-2: Change in p-cresil sulfate in plasma from the start of administration (μg / mL), Table 2-2-1: Amount of p-cresil sulfate in early morning urine (μg / mL), Table 2-2-2: Change in p-cresil sulfate in early morning urine from the start of administration (μg / mL), Table 2-3-1: Ratio of p-cresil sulfate in urine to p-cresil sulfate in plasma. Table 2-3-2: Change from the start of administration in the ratio of p-cresil sulfate in urine to p-cresil sulfate in plasma. Table 3-1-1: Hippuric acid amount in plasma (μg / mL), Table 3-1-2: Change in plasma hippuric acid from the start of administration (μg / mL), Table 3-2-1: Hippuric acid content in early morning urine (μg / mL), Table 3-2-2: Change in hippuric acid in early morning urine from the start of administration (μg / mL), Table 3-3-1: Ratio of hippuric acid in urine to hippuric acid in plasma. Table 3-3-2: Change in the ratio of hippuric acid in urine to hippuric acid in plasma from the start of administration. Table 4-1-1: Alginosuccinate content in plasma (μg / mL), Table 4-1-2: Change in plasma arginosuccinate from the start of administration (μg / mL), Table 4-2-1: Alginosuccinate content in early morning urine (μg / mL), Table 4-2-2: Change in arginosuccinate in early morning urine from the start of administration (μg / mL), Table 4-3-1: Ratio of arginosuccinate in urine to arginosuccinate in plasma. Table 4-3-2: Change from the start of administration in the ratio of arginosuccinate in urine to arginosuccinate in plasma. Table 5-1-1: Plasma phenylacetyl-L-glutamine (PAG) levels (μg / mL), Table 5-1-2: Change in plasma phenylacetyl-L-glutamine (PAG) levels from the start of administration (μg / mL), Table 5-2-1: Phenylates-L-glutamine (PAG) in early morning urine (μg / mL) Table 5-2-2: Change in phenylacetyl-L-glutamine (PAG) in early morning urine from the start of administration (μg / mL), Table 5-3-1: Ratio of phenylacetyl-L-glutamine (PAG) levels in urine to phenylacetyl-L-glutamine (PAG) levels in plasma. Table 5-3-2: Change from the start of administration in the ratio of phenylacetyl-L-glutamine (PAG) levels in urine to phenylacetyl-L-glutamine (PAG) levels in plasma.
[0042] In group A (Citrate: administered a potassium citrate / sodium citrate hydrate preparation), indoxyl sulfate (IS) concentration in early morning urine increased compared to group B (Bicarbonate: administered a sodium bicarbonate preparation) and group C (Control) (see Tables 1-2-1 and 1-2-2). In addition, plasma indoxyl sulfate concentration decreased in group A compared to groups B and C (see Tables 1-1-1 and 1-1-2). Plasma indoxyl sulfate concentrations at weeks 6–24 were significantly lower in group A compared to groups B and C, and the increase in indoxyl sulfate concentration in early morning urine at weeks 6–24 was significantly greater in group A compared to groups B and C. Furthermore, administration of a potassium citrate / sodium citrate hydrate formulation to patients with chronic kidney disease resulted in an increase in the urinary concentration of indoxyl sulfate, a uremic substance, compared to before administration, and a decrease in the blood concentration of indoxyl sulfate compared to before administration. Compared to sodium bicarbonate, which is also an alkalizing agent, the potassium citrate / sodium citrate hydrate formulation exhibited a greater effect in reducing blood indoxyl sulfate concentration and increasing urinary indoxyl sulfate concentration. The effects of the potassium citrate / sodium citrate hydrate formulation on reducing blood indoxyl sulfate concentration and increasing urinary indoxyl sulfate concentration were observed from 12 weeks after administration. The ratio of indoxyl sulfate concentration in urine to indoxyl sulfate concentration in plasma suggests that administration of a potassium citrate / sodium citrate hydrate formulation promotes the excretion of indoxyl sulfate from the blood into the urine, thereby facilitating its removal from the body. Furthermore, the effect of administering the potassium citrate / sodium citrate hydrate formulation on the excretion of indoxyl sulfate from the blood into the urine was suggested to be stronger than that of administering a sodium bicarbonate formulation (see Tables 1-3-1 and 1-3-2).
[0043] [Table 1-1-1]
[0044] [Table 1-1-2]
[0045] [Table 1-2-1]
[0046] [Table 1-2-2]
[0047] [Table 1-3-1]
[0048] [Table 1-3-2]
[0049] Regarding p-cresyl sulfate (PCS), the concentration of p-cresyl sulfate in early morning urine increased in Group A (Citrate: group administered a potassium citrate / sodium citrate hydrate preparation) compared with Group C (Control: control group), and also increased in Group A (potassium citrate / sodium citrate hydrate preparation) compared with Group B (Bicarbonate: group administered a sodium bicarbonate preparation) (see Tables 2-2-1 and 2-2-2). The increase in p-cresyl sulfate concentration in early morning urine from weeks 6 to 24 was significantly greater in Group A compared with Groups B and C. Furthermore, administration of a potassium citrate / sodium citrate hydrate formulation to patients with chronic kidney disease increased the urinary concentration of p-cresyl sulfate, a uremic substance, compared to before administration (see Tables 2-2-1 and 2-2-2). Even among alkalizing agents, the potassium citrate / sodium citrate hydrate formulation exhibited a greater effect in increasing urinary p-cresyl sulfate concentration compared to sodium bicarbonate formulations. The effect of the potassium citrate / sodium citrate hydrate formulation on increasing urinary p-cresyl sulfate concentration was observed from 12 weeks after administration. The ratio of p-cresyl sulfate concentration in urine to p-cresyl sulfate concentration in plasma suggests that administration of a potassium citrate / sodium citrate hydrate formulation promotes the excretion of p-cresyl sulfate from the blood into the urine, thereby facilitating its removal from the body. Furthermore, the effect of administering the potassium citrate / sodium citrate hydrate formulation on the excretion of p-cresyl sulfate from the blood into the urine was suggested to be stronger than that of administering a sodium bicarbonate formulation (see Tables 2-3-1 and 2-3-2).
[0050] [Table 2-1-1]
[0051] [Table 2-1-2]
[0052] [Table 2-2-1]
[0053] [Table 2-2-2]
[0054] [Table 2-3-1]
[0055] [Table 2-3-2]
[0056] Regarding hippuric acid (HA), the concentration of hippuric acid in early morning urine increased in group A (Citrate: group administered a potassium citrate / sodium citrate hydrate combination preparation) compared with group C (Control: control group) (see Tables 3-2-1 and 3-2-2). Furthermore, administration of a potassium citrate / sodium citrate hydrate formulation to patients with chronic kidney disease increased the urinary concentration of hippuric acid, a uremic substance, compared to before administration (see Tables 3-2-1 and 3-2-2). Even among alkalizing agents, the potassium citrate / sodium citrate hydrate formulation exhibited a greater effect in increasing urinary hippuric acid concentration compared to sodium bicarbonate formulations. The effect of the potassium citrate / sodium citrate hydrate formulation on increasing urinary hippuric acid concentration was observed from 6 weeks after administration. Administration of the potassium citrate / sodium citrate hydrate formulation to patients with chronic kidney disease resulted in a decrease in plasma hippuric acid concentration compared to before administration from 24 weeks after administration. Such an effect was not observed with the administration of sodium bicarbonate formulations.
[0057] [Table 3-1-1]
[0058] [Table 3-1-2]
[0059] [Table 3-2-1]
[0060] [Table 3-2-2]
[0061] [Table 3-3-1]
[0062] [Table 3-3-2]
[0063] Regarding argininosuccinate (ASA), the concentration of argininosuccinate in early morning urine increased in group A (Citrate: group administered a potassium citrate / sodium citrate hydrate combination preparation) compared with group C (Control: control group) (see Tables 4-2-1 and 4-2-2). Furthermore, administration of a potassium citrate / sodium citrate hydrate formulation to patients with chronic kidney disease resulted in an increase in the urinary concentration of argininosuccinate, a uremic substance, compared to before administration (see Tables 4-2-1 and 4-2-2). The effect of the potassium citrate / sodium citrate hydrate formulation on increasing urinary argininosuccinate concentration was observed from 12 weeks after administration.
[0064] [Table 4-1-1]
[0065] [Table 4-1-2]
[0066] [Table 4-2-1]
[0067] [Table 4-2-2]
[0068] [Table 4-3-1]
[0069] [Table 4-3-2]
[0070] Regarding phenylacetyl-L-glutamine (PAG), Group A (Citrate: group administered a potassium citrate / sodium citrate hydrate combination preparation) showed a decrease in plasma phenylacetyl-L-glutamine concentration and an increase in phenylacetyl-L-glutamine concentration in early morning urine compared to Group C (Control: control group). Compared to Group B (Bicarbonate: group administered a sodium bicarbonate preparation), Group A (potassium citrate / sodium citrate hydrate combination preparation) also showed an increase in phenylacetyl-L-glutamine concentration in early morning urine (see Tables 5-1-1 and 5-2-2). Furthermore, administration of a potassium citrate / sodium citrate hydrate formulation to patients with chronic kidney disease increased the urinary concentration of phenylacetyl-L-glutamine, a uremic substance, compared to before administration (see Tables 5-2-1 and 5-2-2). Even among alkalizing agents, the potassium citrate / sodium citrate hydrate formulation exhibited a greater effect in increasing urinary phenylacetyl-L-glutamine concentration compared to sodium bicarbonate formulations. The effect of the potassium citrate / sodium citrate hydrate formulation on increasing urinary phenylacetyl-L-glutamine concentration was observed from 12 weeks after administration. Administration of a potassium citrate / sodium citrate hydrate formulation to patients with chronic kidney disease decreased the plasma concentration of phenylacetyl-L-glutamine, a uremic substance, compared to before administration (see Tables 5-1-1 and 5-2-2). The ratio of phenylacetyl-L-glutamine concentration in urine to phenylacetyl-L-glutamine concentration in plasma suggests that administration of a potassium citrate / sodium citrate hydrate formulation promotes the excretion of phenylacetyl-L-glutamine from the blood into the urine, thereby facilitating its removal from the body. Furthermore, the effect of administering the potassium citrate / sodium citrate hydrate formulation on the excretion of phenylacetyl-L-glutamine from the blood into the urine was suggested to be stronger than that of administering a sodium bicarbonate formulation (see Tables 5-3-1 and 5-3-2).
[0071] [Table 5-1-1]
[0072] [Table 5-1-2]
[0073] [Table 5-2-1]
[0074] [Table 5-2-2]
[0075] [Table 5-3-1]
[0076] [Table 5-3-2]
[0077] The effects of potassium citrate / sodium citrate hydrate (Citrate) and sodium bicarbonate preparations on plasma concentrations, early morning urine concentrations, and the ratio of early morning urine concentrations to plasma concentrations for each uremic substance are summarized in the table below. In the table below, the control drug is sodium bicarbonate preparation in the case of potassium citrate / sodium citrate hydrate (Citrate), and sodium bicarbonate preparation in the case of sodium bicarbonate preparation (Bicarbonate). ○ is indicated when the effect is significantly superior to the control group or the control drug group, × is indicated when the effect is significantly inferior to the control group or the control drug group, and - is indicated when there is no significant difference. Note that the effect of the sodium bicarbonate preparation group on indoxyl sulfate concentration in early morning urine compared to the control group is indicated with (○) in the table below. This is because, while the group administered sodium bicarbonate showed a significantly increased concentration of indoxyl sulfate in early morning urine compared to the control group, the concentration of indoxyl sulfate in early morning urine after administration of sodium bicarbonate decreased compared to the start of administration. Therefore, it is not possible to determine whether or not the sodium bicarbonate administration has a promoting effect on the urinary excretion of indoxyl sulfate.
[0078] [Table 6]
[0079] From the table above, it can be seen that, in general, preparations containing potassium citrate and sodium citrate hydrate exhibit a higher excretion effect of uremic substances from the body compared to preparations containing sodium bicarbonate. Furthermore, it was suggested that administering alkalizing agents to patients with chronic kidney disease not only in stage G3b but also in stage G2 can suppress the progression of chronic kidney disease, and that preparations containing potassium citrate and sodium citrate hydrate suppress the progression of chronic kidney disease more effectively than those containing sodium bicarbonate.
Claims
1. A pharmaceutical composition containing an alkalizing agent for promoting the excretion of uremic substances from the body.
2. A pharmaceutical composition containing an alkalizing agent for reducing the blood concentration of uremic substances.
3. A pharmaceutical composition containing an alkalizing agent for promoting the urinary excretion of uremic substances.
4. A pharmaceutical composition according to any one of claims 1 to 3, administered to a patient with chronic kidney disease or acute kidney disease.
5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the uremic substance is selected from the group consisting of indoxyl sulfate, p-cresyl sulfate, phenylacetyl-L-glutamine, hippuric acid, and argininosuccinic acid.
6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the uremic substance is indoxyl sulfate and phenylacetyl-L-glutamine.
7. A pharmaceutical composition according to any one of claims 1 to 6, wherein the uremic substance is indoxyl sulfate.
8. A pharmaceutical composition containing an alkalizing agent for improving uremic symptoms in chronic kidney disease.
9. A pharmaceutical composition containing an alkalizing agent for delaying the initiation of dialysis in chronic kidney disease.
10. A pharmaceutical composition containing an alkalizing agent for the treatment or prevention of cardiovascular disease associated with chronic kidney disease.
11. A pharmaceutical composition according to claim 10, which improves arteriosclerosis.
12. A pharmaceutical composition containing an alkalizing agent for inhibiting the progression of chronic kidney disease.
13. A pharmaceutical composition according to any one of claims 1 to 12, to be administered to patients with early-stage chronic kidney disease.
14. A pharmaceutical composition according to any one of claims 1 to 13, administered to patients with chronic renal failure of stage G3b or lower.
15. A pharmaceutical composition according to any one of claims 1 to 14, administered to a patient with stage G2 chronic renal failure.
16. A pharmaceutical composition containing an alkalizing agent for inhibiting the progression from acute kidney disease to chronic kidney disease.
17. The pharmaceutical composition according to any one of claims 1 to 16, wherein the alkalizing agent is a pharmaceutically acceptable salt of citric acid, a hydrate thereof, or a mixture thereof.
18. The pharmaceutical composition according to any one of claims 1 to 17, wherein the alkalizing agent is sodium citrate, potassium citrate, or its hydrate, or a mixture thereof.
19. The pharmaceutical composition according to any one of claims 1 to 18, wherein the alkalizing agent is sodium citrate or its hydrate.
20. A pharmaceutical composition according to any one of claims 1 to 19, wherein the alkalizing agent is designed to be administered in an amount that improves acidic urine in gout or hyperuricemia.
21. A pharmaceutical composition according to any one of claims 1 to 20, wherein the alkalizing agent is administered over a long period of time.
22. The pharmaceutical composition according to any one of claims 1 to 21, wherein the alkalizing agent is administered over a period of six weeks or more.
23. The pharmaceutical composition according to any one of claims 1 to 22, wherein the concentration of uremic substances in the blood decreases compared to before administration upon administration of an alkalizing agent.
24. The pharmaceutical composition according to any one of claims 1 to 23, wherein the concentration of uremic substances in the urine increases compared to before administration upon administration of an alkalizing agent.
25. A pharmaceutical composition according to any one of claims 1 to 24, wherein the pharmaceutical composition is a tablet.
26. A food composition containing an alkalizing agent for promoting the excretion of uremic substances from the body.
27. The food composition according to claim 26, wherein the alkalizing agent is an alkali metal citrate salt or its hydrate or a mixture thereof.
28. A method for determining the suppression of the progression of chronic kidney disease, comprising measuring the pH of urine.
29. A method for determining a decrease in the concentration of uremic substances in the blood of a patient with chronic kidney disease, comprising measuring the pH of the urine.
30. A method for determining the promotion of excretion of uremic substances into the urine of patients with chronic kidney disease, comprising measuring the pH of the urine.
Citation Information
Cited By
Blood purification through alkalifying agent
JP2024133407A
